In 1997, the U.S. Department of Health and Human Services (HHS) appointed the Institute of Medicine (IOM) of the U.S. National Academy of Sciences (NAS) to investigate the potential risks of operative and post-operative complications from the emplacement of silicone breast implants. The IOM's review of the safety and efficacy of silicone gel-filled breast implants, reported that the "evidence suggests diseases or conditions, such as connective tissue diseases, cancer, neurological diseases, or other systemic complaints or conditions are no more common in women with breast implants, than in women without implants" subsequent studies and systemic review found no causal link between silicone breast implants and disease.
As with any sort of surgery there are always risks involved. The two most common risks for breast implant surgery are bleeding and infection. In general, the risk of bleeding is very low, and if it does happen, it will typically happen within the first 24 hours. Infection on the other hand, can take up to one to two weeks to before it will show itself. However, we take every possible precaution such as; using sterile equipment, sterile gowns, gloves, masks and many other safety precautions. The risk of infection is typically anywhere from two to three percent. So yes, there are risks and they can happen but they are very rare. One other risk that needs to be mentioned is the risk of using anesthesia. So yes, it can happen, but it’s exceedingly rare.
It is certainly possible to lift a breast without changing the volume or removing any tissue, however, the breast will sometimes appear smaller after this procedure due to its position. It is also possible to reduce breast volume without lifting the tissue (usually via liposuction) but all reductions that are performed by making incisions will also include a lift.
Prepectoral or subcutaneous: in a breast reconstruction following a skin-sparing or skin- and nipple-sparing mastectomy, the implant is placed above the pectoralis major muscle without dissecting it so that the implant fills directly the volume of the mammary gland that has been removed. To avoid the issue of capsular contracture, the implant is often covered frontally or completely with a mesh in biomaterial, either biological or synthetic.
A: During your initial consultation, you will discuss your desired results with Dr. Hochstein so he can fully understand your expectations. You will be provided with before and after photos so that you can see some of the results Dr. Hochstein has achieved with his other patients. He will examine your breasts and evaluate other factors that may affect the outcome of your surgery. This will help determine the appropriate breast size and incision location.
This includes the cost of the implants, which ranges from $1,000 to $1,300 as well as a facility fee of $800 to $1,200, an anesthesia fee of $600 to $800 and the surgeon's fee that averages $4,005 for silicone-gel filled implants and $3,583 for saline implants. Patients in the western United States can expect to pay the highest average surgeon's fee of about $3,949, while patients in the south central part of the country generally pay lower fees with an average of $2,739.
The breast implant has no clinical bearing upon lumpectomy breast-conservation surgery for women who developed breast cancer after the implantation procedure, nor does the breast implant interfere with external beam radiation treatments (XRT); moreover, the post-treatment incidence of breast-tissue fibrosis is common, and thus a consequent increased rate of capsular contracture. The study Breast Cancer Detection and Survival among Women with Cosmetic Breast Implants: Systematic Review and Meta-analysis of Observational Studies, reported an average later stage in the diagnoses of women who developed breast cancer after undergoing breast augmentation, when compared to breast cancer patients who had not undergone breast augmentation, although this did not ultimately affect the patients prognosis. The use of implants for breast reconstruction after breast cancer mastectomy appears to have no negative effect upon the incidence of cancer-related death.
In 1988, twenty-six years after the 1962 introduction of breast implants filled with silicone gel, the U.S. Food and Drug Administration (FDA) investigated breast implant failures and the subsequent complications, and re-classified breast implant devices as Class III medical devices, and required from manufacturers the documentary data substantiating the safety and efficacy of their breast implant devices. In 1992, the FDA placed silicone-gel breast implants in moratorium in the U.S., because there was “inadequate information to demonstrate that breast implants were safe and effective”. Nonetheless, medical access to silicone-gel breast implant devices continued for clinical studies of post-mastectomy breast reconstruction, the correction of congenital deformities, and the replacement of ruptured silicone-gel implants. The FDA required from the manufacturers the clinical trial data, and permitted their providing breast implants to the breast augmentation patients for the statistical studies required by the U.S. Food and Drug Administration. In mid–1992, the FDA approved an adjunct study protocol for silicone-gel filled implants for breast reconstruction patients, and for revision-surgery patients. Also in 1992, the Dow Corning Corporation, a silicone products and breast implant manufacturer, announced the discontinuation of five implant-grade silicones, but would continue producing 45 other, medical-grade, silicone materials—three years later, in 1995, the Dow Corning Corporation went bankrupt when it faced large class action lawsuits claiming a variety of illnesses.
When estimating your cost for breast augmentation surgery, make sure to account for all of these fees. You should ask the surgeon directly if these are all the costs involved in your estimate. Since there are no set costs for any of these expenses, it is important to explore multiple options by meeting with several surgeons and getting estimates for not only their surgeon fees but also the additional surgical-related expenses.
MENTOR® MemoryGel® Breast Implants, MENTOR® MemoryShape® Breast Implants, and MENTOR® Saline-filled Breast Implants are indicated for breast augmentation in women (at least 22 years old for MemoryGel® Implants and MemoryShape® Implants, and 18 years old for Saline Implants) or for breast reconstruction. Breast implant surgery should not be performed in women with active infection anywhere in their body, with existing cancer or pre-cancer of their breast who have not received adequate treatment for those conditions, or who are currently pregnant or nursing.
Despite their differences, most patients who have these procedures to attain their specific goals are highly satisfied with their results. Both procedures are relatively easy to recover from and require 2 to 4 weeks of downtime. Even though both procedures address different issues, it is not unusual for women to encounter both excess breast tissue and sagging. Commonly, these women get the best results by receiving a combination of breast reduction and breast lift procedures. If you are considering a breast reduction, breast lift or a combination of the two, do your research and find a skilled board-certified plastic surgeon to discuss which one is right for your specific goals.
Your plastic surgeon will give you instructions on how to prevent these complications. If you have a high temperature, it’s a sign of an infection. If you monitor your temperature daily, you’ll be able to head off an infection in the early stages. Darkening of the skin is another red flag sign and your surgeon should be notified almost immediately. Vomiting, convulsions and loss of consciousness are signs that something needs to be checked medically – quickly.
2000 European Union European Committee on Quality Assurance & Medical Devices in Plastic Surgery (EQUAM) "Additional medical studies have not demonstrated any association between silicone-gel filled breast implants and traditional auto-immune or connective tissue diseases, cancer, nor any other malignant disease. . . . EQUAM continues to believe that there is no scientific evidence that silicone allergy, silicone intoxication, atypical disease or a 'new silicone disease' exists."